Annexon, Inc.

Annexon maintains a strong liquidity position with $175.2 million in cash and equivalents against total liabilities of $58.4 million, resulting in a current ratio of 6.35 and zero debt-to-equity. The company holds a market capitalization of $989.5 million, trading at a price-to-book ratio of 4.84, which reflects investor premium for its clinical pipeline despite negative earnings. Operating cash flow was negative $46.8 million in Q1 2026, consistent with its pre-revenue status and heavy investment in research and development. The absence of capital expenditures indicates that cash burn is primarily driven by operational costs rather than asset acquisition.

Profitability metrics are deeply negative, with a return on equity of -21.58% and return on assets of -16.79%, reflecting the company's stage of development. Net income for Q1 2026 was a loss of $44.1 million, slightly improved from the $54.4 million loss in the same period of the prior year. The company does not generate revenue, so traditional margin analysis is not applicable; instead, efficiency is measured by the rate of cash consumption relative to clinical progress. The negative EV/EBITDA of -17.89 is a function of negative earnings and does not provide a meaningful valuation comparison to profitable peers.

As a clinical-stage entity, Annexon has no reported revenue segments or geographic sales mix. The company's value is derived entirely from its intellectual property and clinical trial results, specifically its lead candidate ANX005 for Huntington's disease and ANX1502 for complement-mediated diseases. The lack of commercial revenue means there is no concentration risk in terms of customer or product sales, but the business is entirely dependent on the success of its R&D pipeline.

Growth trajectory is defined by clinical milestones rather than financial expansion. The company reported stabilization of disease progression in its Huntington's disease study over nine months, a key proof-of-concept result. Recent financing activities include $33.6 million in proceeds from the issuance of common stock in Q1 2026, indicating active capital raising to support ongoing trials. The company's cash position increased by $13.2 million in Q1 2026, driven by financing activities and net cash provided by investing activities from securities maturities.

Risk assessment highlights high dilution risk, with the diluted share count of 194.2 million significantly exceeding the basic share count of 149.4 million. This discrepancy suggests substantial outstanding options, warrants, or convertible instruments that could erode shareholder value upon exercise. Liquidity risk is assessed as low due to the strong cash balance, but the company's reliance on external financing for long-term survival introduces execution risk. The company has disclosed forward-looking statements regarding its ability to raise additional capital, acknowledging the uncertainty of future funding needs.

Recent events include an 8-K filing with high-severity items related to material agreements and financial statements, alongside analyst coverage showing a mean price target of $14.33 and a mean recommendation of 2.08 (buy). The company continues to advance its clinical programs, with plans to evaluate ANX1502 in serious complement-mediated diseases following proof-of-concept studies. The partial coverage in company facts and backfilled share data indicates ongoing refinement of its public financial disclosures.

Operating income -$46.1M.

• ▍Operating income -$46.1M

Operating income -$166.1M.

• ▍Operating income -$166.1M

Operating income -$109.1M.

• ▍Operating income -$109.1M

Operating income -$216.4M.

• ▍Operating income -$216.4M

Operating income -$154.1M.

• ▍Operating income -$154.1M

Operating income -$154.1M.

• ▍Operating income -$154.1M

Operating income -$143.7M.

• ▍Operating income -$143.7M

Operating income -$143.7M.

• ▍Operating income -$143.7M